Prelude Therapeutics Inc (PRLD)

Dec 20, 2024

Krishna Vaddi Buys 100,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock - MarketBeat

Dec 20, 2024

Dec 20, 2024

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Acquires $22,750.00 in Stock - MarketBeat

Dec 20, 2024

Dec 20, 2024

Prelude Therapeutics CEO Krishna Vaddi buys $99,325 in stock - Investing.com India

Dec 20, 2024

Dec 20, 2024

Prelude Therapeutics CEO Krishna Vaddi buys $99,325 in stock By Investing.com - Investing.com Canada

Dec 20, 2024

Dec 20, 2024

Prelude Therapeutics' interim CFO Bryant Lim buys $22,637 in stock - Investing.com

Dec 20, 2024

Dec 19, 2024

Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo

Dec 19, 2024

Dec 16, 2024

What Did We Find About Insider Trading At Prelude Therapeutics Inc (NASDAQ: PRLD)? - Stocks Register

Dec 16, 2024

Dec 15, 2024

Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com Canada

Dec 15, 2024

Dec 14, 2024

Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MyChesCo

Dec 14, 2024

Dec 13, 2024

PRLD Stock Touches 52-Week Low at $0.91 Amid Market Challenges - Investing.com Canada

Dec 13, 2024

Dec 13, 2024

Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MyChesCo

Dec 13, 2024

Dec 12, 2024

Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MyChesCo

Dec 12, 2024

Dec 12, 2024

Windtree Therapeutics Files Patent for Istaroxime Derivatives to Combat Acute Myocardial Arrhythmia - MyChesCo

Dec 12, 2024

Dec 12, 2024

Prelude Therapeutics presents first interim data from trial of PRT2527 - Yahoo Finance

Dec 12, 2024

Dec 12, 2024

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Position Increased by Walleye Capital LLC - Defense World

Dec 12, 2024

Dec 11, 2024

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 - The Bakersfield Californian

Dec 11, 2024

Dec 11, 2024

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies - Yahoo Finance

Dec 11, 2024

Dec 10, 2024

Sirus Therapeutics announces positive signals from Phase I siRNA trial - Yahoo Finance

Dec 10, 2024

Dec 05, 2024

PRLD Stock Touches 52-Week Low at $0.93 Amid Market Challenges - Investing.com Nigeria

Dec 05, 2024

Nov 29, 2024

November 2024's Top Picks: Penny Stocks On US Exchanges - Simply Wall St

Nov 29, 2024

Nov 27, 2024

After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD) - Yahoo Finance

Nov 27, 2024

Nov 27, 2024

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - Yahoo Finance

Nov 27, 2024

Nov 25, 2024

Prelude Therapeutics Reports Progress in Clinical Trials and Financial Health - TipRanks

Nov 25, 2024

Nov 21, 2024

Panavance Therapeutics Unveils Promising Data on Misetionamide’s Dual Cancer Targeting Mechanism - MyChesCo

Nov 21, 2024

Nov 21, 2024

Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MyChesCo

Nov 21, 2024

Nov 20, 2024

Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) - MSN

Nov 20, 2024

Nov 17, 2024

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update - MarketBeat

Nov 17, 2024

Nov 15, 2024

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

PRLD Stock Touches 52-Week Low at $1.1 Amid Market Challenges - Investing.com Australia

Nov 14, 2024

Nov 13, 2024

Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts - Investing.com

Nov 13, 2024

Nov 12, 2024

Tectonic Therapeutic Inc. Reports Q3 2024 Results - Yahoo Finance

Nov 12, 2024

Nov 12, 2024

Prelude Therapeutics (NASDAQ:PRLD) Receives Buy Rating from HC Wainwright - Defense World

Nov 12, 2024

Nov 10, 2024

Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 10, 2024

Nov 09, 2024

Prelude Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN

Nov 09, 2024

Nov 09, 2024

Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials - MyChesCo

Nov 09, 2024

Nov 08, 2024

Prelude Therapeutics (NASDAQ:PRLD) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 08, 2024

Nov 08, 2024

Context Therapeutics Announces Q3 2024 Financial Results and Strategic Advances - MyChesCo

Nov 08, 2024

Nov 07, 2024

Mineralys Therapeutics to Announce Third-Quarter 2024 Financial Results - MyChesCo

Nov 07, 2024

Nov 07, 2024

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 07, 2024

Oct 31, 2024

PRLD stock touches 52-week low at $1.32 amid market challenges - Investing.com Australia

Oct 31, 2024

Oct 31, 2024

Prelude Therapeutics’ (PRLD) Buy Rating Reiterated at HC Wainwright - Defense World

Oct 31, 2024

Oct 30, 2024

PRLD stock touches 52-week low at $1.32 amid market challenges By Investing.com - Investing.com South Africa

Oct 30, 2024

Oct 30, 2024

Ocugen to Spotlight Gene Therapy Advances at Upcoming Clinical Showcase - MyChesCo

Oct 30, 2024

Oct 28, 2024

Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts By Investing.com - Investing.com South Africa

Oct 28, 2024

Oct 28, 2024

Prelude Therapeutics (NASDAQ:PRLD) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 28, 2024

Oct 27, 2024

Prelude Therapeutics price target lowered to $1 from $3 at Barclays - Yahoo Finance

Oct 27, 2024